A beacon for people living with severe rare metabolic disorders
Azafaros is a company that seeks to develop new treatments to meet the needs of patients suffering from rare genetic metabolic disorders. We will do this by bringing together our deep understanding of these diseases and our extensive experience in developing new therapies, combined with the newest scientific insights.
We are proud to collaborate with Professor Hans Aerts, whose team led the discovery of AZ-3102, and the University of Leiden.
Equally important to our scientific approach is the collaboration with patients and patient organizations, to learn from their experience in living with these indications and where we as company can make a significant difference for them and their families.
Azafaros is inspired by patients and their families to start the journey toward disease-altering treatment options. In this section we aim to be a resource and provide the most up-to-date information on our progress as well as contribute to our ongoing dialogue with the patient community and the clinicians who treat them.